proxyvotesnow.com

Home › Companies › AKERO THERAPEUTICS INC. › 2024-2025

AKERO THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and AKERO THERAPEUTICS INC.’s Form 8-K, filed June 4, 2025 (Item 5.07 on EDGAR). Page generated October 14, 2026.

  • 4Ballot items
  • 253Asset managers
  • 1,318Fund votes
  • June 3, 2025Meeting date

Results at a glance

Meeting of June 3, 2025: 4 items on AKERO THERAPEUTICS INC.’s Form 8-K, filed June 4, 2025: 4 without a stated outcome.

Material dissent

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AKERO THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by AKERO THERAPEUTICS INC.

These tallies are AKERO THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AKERO THERAPEUTICS INC. — official shareholder meeting results, meeting held June 3, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Judy Chou, Ph.D. 46,654,444---- 15,405,8995,333,604 75%Not verified—
Elect Director: Tomas Heyman 28,017,151---- 34,043,1925,333,604 45.1%Not verified—
The Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2. 67,325,60338,56429,780 --0 99.9%Not verified—
The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3. 60,698,2631,199,541162,539 --5,333,604 98%Not verified—

Source: AKERO THERAPEUTICS INC., Form 8-K, filed with the SEC on June 4, 2025 — read the filing on EDGAR.

How asset managers voted at the AKERO THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 253 asset managers that disclosed a AKERO THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Judy Chou, Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%WITHHELD
FOR: 46,654,444WITHHELD: 15,405,899
Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Judy Chou, Ph.D.

AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Judy Chou, Ph.D.”): 46,654,444 for, 15,405,899 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 75% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 18,317,301 for, 6,798,202 withheld, 135,430 abstained.

FORWITHHOLD
FOR: 18,317,301ABSTAIN: 135,430WITHHOLD: 6,798,202
Largest asset managers voting on “To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until” at AKERO THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard7,781,0050 00For
T. Rowe Price00 03,360,888Withhold
Fidelity2,614,1740 00For
JANUS INVESTMENT FUND2,139,4670 00For
BlackRock1,750,1140 00For
State Street974,7430 01,097For
ACAP Strategic Fund00 0743,040Withhold
Charles Schwab588,4550 00For
TIAA415,1140 00For
AllianceBernstein00 0406,747Withhold
Aberdeen00 0406,700Withhold
Principal1590 0304,719Withhold
Equitable118,8440 0185,900Mixed
ALGER FUNDS00 0302,068Withhold
Loomis Sayles280,1570 00For
AB DISCOVERY GROWTH FUND, INC.00 0239,130Withhold
Hartford229,2550 00For
Advantage Advisers Xanthus Fund, L.L.C.00 0211,967Withhold
MUTUAL FUND SERIES TRUST200,0000 00For
Yiheng Capital Management, L.P.176,2600 00For
Brighthouse76,6310 096,678Mixed
Columbia Threadneedle153,3350 00For
Dimensional00 0135,214Withhold
QUANTITATIVE MASTER SERIES LLC126,8460 00For
John Hancock28,7600 65,9710Mixed

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

2. Elect Director: Tomas Heyman

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

45.1% Plurality election · of votes cast

FOR 45.1%WITHHELD
FOR: 28,017,151WITHHELD: 34,043,192
Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Tomas Heyman

AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Tomas Heyman”): 28,017,151 for, 34,043,192 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 45.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 7,914,497 for, 15,092,151 withheld, 2,244,285 abstained.

FORWITHHOLD
FOR: 7,914,497ABSTAIN: 2,244,285WITHHOLD: 15,092,151
Largest asset managers voting on “To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until” at AKERO THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,122,8820 03,658,123Mixed
T. Rowe Price00 03,360,888Withhold
Fidelity1,011,5880 01,602,586Mixed
JANUS INVESTMENT FUND2,139,4670 00For
BlackRock109,9660 1,640,1480Mixed
State Street2,2700 0973,570Withhold
ACAP Strategic Fund00 0743,040Withhold
Charles Schwab00 0588,455Withhold
TIAA00 0415,114Withhold
AllianceBernstein00 0406,747Withhold
Aberdeen00 0406,700Withhold
Principal00 0304,878Withhold
Equitable00 0304,744Withhold
ALGER FUNDS00 0302,068Withhold
Loomis Sayles00 280,1570Abstain
AB DISCOVERY GROWTH FUND, INC.00 0239,130Withhold
Hartford00 0229,255Withhold
Advantage Advisers Xanthus Fund, L.L.C.00 0211,967Withhold
MUTUAL FUND SERIES TRUST200,0000 00For
Yiheng Capital Management, L.P.176,2600 00For
Brighthouse8,0190 0165,290Withhold
Columbia Threadneedle00 0153,335Withhold
Dimensional00 0135,214Withhold
QUANTITATIVE MASTER SERIES LLC00 126,8460Abstain
John Hancock00 94,7310Abstain

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

3. The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive…

Outcome not verifiedFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 11 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 60,698,263AGAINST: 1,199,541
Details: description as filed, official tally, votes by 253 asset managers

Description as filed by funds: To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive officers.

AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3.”): 60,698,263 for, 1,199,541 against, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 79 asset managers voting on “To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive offi” at AKERO THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard7,780,384621 00For
T. Rowe Price3,360,8880 00For
Fidelity2,614,1740 00For
JANUS INVESTMENT FUND2,139,4670 00For
BlackRock1,750,1140 00For
State Street975,8400 00For
ACAP Strategic Fund743,0400 00For
Charles Schwab588,4550 00For
TIAA415,1140 00For
AllianceBernstein406,7470 00For
Aberdeen406,7000 00For
Principal304,8780 00For
Equitable304,7440 00For
ALGER FUNDS302,0680 00For
Loomis Sayles280,1570 00For
AB DISCOVERY GROWTH FUND, INC.239,1300 00For
Hartford229,2550 00For
Advantage Advisers Xanthus Fund, L.L.C.211,9670 00For
MUTUAL FUND SERIES TRUST200,0000 00For
Brighthouse164,5460 8,7630Mixed
Columbia Threadneedle153,3350 00For
Simplify Exchange Traded Funds00 145,6090Abstain
Dimensional135,2140 00For
QUANTITATIVE MASTER SERIES LLC126,8460 00For
John Hancock94,7310 00For

Fund voting reports, all 79 managers: 25,043,647 for, 22,263 against, 154,372 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 196 asset managers voting on “To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive offi” at AKERO THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP7,419,3400 00For
Janus Henderson6,535,7230 00For
Wellington5,388,9950 00For
T. Rowe Price4,459,3750 00For
BlackRock2,445,3550 00For
State Street2,401,8650 00For
GEODE CAPITAL MANAGEMENT, LLC1,757,9570 00For
MARSHALL WACE, LLP1,693,8050 00For
Deep Track Capital, LP1,407,8060 00For
AllianceBernstein1,160,9040 00For
Fidelity1,008,4420 00For
Logos Global Management LP949,6550 00For
Redmile Group, LLC849,7150 00For
Point72775,4540 00For
PERCEPTIVE ADVISORS LLC673,7950 00For
Rock Springs Capital Management LP669,1470 00For
PICTET ASSET MANAGEMENT SA616,4690 00For
Charles Schwab595,1330 00For
ALKEON CAPITAL MANAGEMENT LLC567,3080 00For
Woodline Partners LP505,9740 00For
Northern Trust496,8970 00For
Loomis Sayles474,9860 00For
Nuveen420,8470 00For
SILVERARC CAPITAL MANAGEMENT, LLC409,7760 00For
Aberdeen406,7000 00For

Institutional-manager reports, all 196 managers: 49,661,214 for, 458,253 against, 20 not voted. Showing the 25 largest; see all in the interactive database.

4. The Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2.

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 67,325,603AGAINST: 38,564
Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2.”): 67,325,603 for, 38,564 against, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 25,241,336 for, 834 against, 8,763 abstained.

FOR
FOR: 25,241,336AGAINST: 834ABSTAIN: 8,763
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR TH” at AKERO THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard7,781,0050 00For
T. Rowe Price3,360,8880 00For
Fidelity2,614,1740 00For
JANUS INVESTMENT FUND2,139,4670 00For
BlackRock1,750,1140 00For
State Street975,8400 00For
ACAP Strategic Fund743,0400 00For
Charles Schwab588,4550 00For
TIAA415,1140 00For
AllianceBernstein406,7470 00For
Aberdeen406,7000 00For
Principal304,8780 00For
Equitable304,7440 00For
ALGER FUNDS302,0680 00For
Loomis Sayles280,1570 00For
AB DISCOVERY GROWTH FUND, INC.239,1300 00For
Hartford229,2550 00For
Advantage Advisers Xanthus Fund, L.L.C.211,9670 00For
MUTUAL FUND SERIES TRUST200,0000 00For
Yiheng Capital Management, L.P.176,2600 00For
Brighthouse164,5460 8,7630Mixed
Columbia Threadneedle153,3350 00For
Dimensional135,2140 00For
QUANTITATIVE MASTER SERIES LLC126,8460 00For
John Hancock94,7310 00For

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

Not shown here: this season’s fund filings also report 1 item from the meeting of June 7, 2024, which belongs to the 2023-2024 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest AKERO THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.

Fund voting reports: top AKERO THERAPEUTICS INC. shareholders by shares voted on “To consider and act upon a non- binding, advisory vote to approve the compensation of our named…”, 2024-2025
#Asset manager Shares voted
1Vanguard 7,781,005
2T. Rowe Price 3,360,888
3Fidelity 2,614,174
4JANUS INVESTMENT FUND 2,139,467
5BlackRock 1,750,114
6State Street 975,840
7ACAP Strategic Fund 743,040
8Charles Schwab 588,455
9TIAA 415,114
10AllianceBernstein 406,747
Institutional-manager reports: top AKERO THERAPEUTICS INC. shareholders by shares voted on “To consider and act upon a non- binding, advisory vote to approve the compensation of our named…”, 2024-2025
#Asset manager Shares voted
1RTW INVESTMENTS, LP 7,419,340
2Janus Henderson 6,535,723
3Wellington 5,388,995
4T. Rowe Price 4,459,375
5BlackRock 2,445,355
6State Street 2,401,865
7GEODE CAPITAL MANAGEMENT, LLC 1,757,957
8MARSHALL WACE, LLP 1,693,805
9Deep Track Capital, LP 1,407,806
10AllianceBernstein 1,160,904

Shown as share counts, not percentages: no shares-outstanding figure has been matched to AKERO THERAPEUTICS INC. for the 2024-2025 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At AKERO THERAPEUTICS INC.'s shareholder meeting held June 3, 2025, in the 2024-2025 proxy season, 253 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,318 separate fund positions. On the most widely held item on that ballot — To consider and act upon a non- binding, advisory vote to approve the compensation of our named… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: AKERO THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2025.

AKERO THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.